Analysis of Phase III Readout
$Geron (GERN.US)$
IMO the phase III result published in the Lancet is not impressive.
1. 40% reaching endpoint versus 15% receiving placebo (doubtful here)
2. 91% Grade 3-4 TEAE, compared to ESA and luspatercept (current standard of care) is insane
3. Even approved, very limited population of patients willing to take
IMO the phase III result published in the Lancet is not impressive.
1. 40% reaching endpoint versus 15% receiving placebo (doubtful here)
2. 91% Grade 3-4 TEAE, compared to ESA and luspatercept (current standard of care) is insane
3. Even approved, very limited population of patients willing to take
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
